Johnson & Johnson and its subsidiary Janssen Pharmaceuticals have agreed to pay $300,000 to the Virgin Islands to settle claims “related to the marketing of the companies antipsychotic drug Risperdal in the Virgin Islands prior to 2008,” according to Virgin Islands Attorney General Claude Earl Walker. Risperdal, known generically as risperidone, is approved in the U.S. for the treatment of schizophrenia, bipolar disorder, and irritability with autism. It is often prescribed off label for behavioral conditions such as ADHD. In 2006, the drug was approved for pediatric use. The Virgin Islands AG’s office claims that Janssen violated the country’s Unfair ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.